Linlin Huang

Shanghai, 200040, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 8 publications

ASB3 limits adipocyte thermogenesis and energy expenditure through p62 ubiquitination.

ASB3 limits adipocyte thermogenesis and energy expenditure through p62 ubiquitination.

Journal: Metabolism: clinical and experimental

Published: June 10, 2026

Author's response to letter to editor.

Author's response to letter to editor.

Journal: Clinical rheumatology

Published: April 02, 2025

Spatial multiomics decipher fibroblast-macrophage dynamics in systemic sclerosis.

Spatial multiomics decipher fibroblast-macrophage dynamics in systemic sclerosis.

Journal: Annals of the rheumatic diseases

Published: February 17, 2025

Hepatocytic ankyrin repeat and SOCS box protein 3 deficiency alleviates metabolic dysfunction-associated steatotic liver disease by decreasing ubiquitin-mediated carnitine palmitoyl transferase 1A.

Hepatocytic ankyrin repeat and SOCS box protein 3 deficiency alleviates metabolic dysfunction-associated steatotic liver disease by decreasing ubiquitin-mediated carnitine palmitoyl transferase 1A.

Journal: Clinical and molecular hepatology

Published: November 25, 2024

The predictive value of anti-IFI16 antibodies for the development or persistence of digital ulcers in systemic sclerosis.

The predictive value of anti-IFI16 antibodies for the development or persistence of digital ulcers in systemic sclerosis.

Journal: Clinical rheumatology

Published: September 05, 2024

Role of ubiquitination-driven metabolisms in oncogenesis and cancer therapy.

Role of ubiquitination-driven metabolisms in oncogenesis and cancer therapy.

Journal: Seminars in cancer biology

Published: August 26, 2024

Identification and validation of anti-protein arginine methyltransferase 5 (PRMT5) antibody as a novel biomarker for systemic sclerosis (SSc).

Identification and validation of anti-protein arginine methyltransferase 5 (PRMT5) antibody as a novel biomarker for systemic sclerosis (SSc).

Journal: Annals of the rheumatic diseases

Published: January 27, 2024

MLN4924 Treatment Diminishes Excessive Lipid Storage in High-Fat Diet-Induced Non-Alcoholic Fatty Liver Disease (NAFLD) by Stimulating Hepatic Mitochondrial Fatty Acid Oxidation and Lipid Metabolites.

MLN4924 Treatment Diminishes Excessive Lipid Storage in High-Fat Diet-Induced Non-Alcoholic Fatty Liver Disease (NAFLD) by Stimulating Hepatic Mitochondrial Fatty Acid Oxidation and Lipid Metabolites.

Journal: Pharmaceutics

Published: October 15, 2022

Showing 1-8 of 8

Last Updated: 09/26/2026